UniProt O94925
Glutaminase kidney isoform, mitochondrial (O94925)
Glutaminase kidney isoform, mitochondrial (UniProt O94925), EC 3.5.1.2: 79 experimental structures and 1 predicted model on GenesisL1, 28 ligands bound, 282 pockets. Binding sites, druggability and experiment against prediction…
- UniProt
- O94925
- Protein
- Glutaminase kidney isoform, mitochondrial
- EC
- 3.5.1.2
- Experimental structures
- 79
- Predicted models
- 1
- Ligands
- 28
- Pockets
- 282 · 25 records with a druggable one
Structures
80 records of O94925 in the MolNFT archive: 79 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 3CZD | Crystal structure of human glutaminase in complex with L-glutamate | x-ray diffraction | A | — | — |
| 3CZD | Crystal structure of human glutaminase in complex with L-glutamate | x-ray diffraction | A | — | — |
| 3UNW | Crystal Structure of Human GAC in Complex with Glutamate | x-ray diffraction | A, B, C, D | — | — |
| 3UNW | Crystal structure of human gac in complex with glutamate | x-ray diffraction | A, B, C, D | — | — |
| 3UO9 | Crystal Structure of Human GAC in Complex with Glutamate and BPTES | x-ray diffraction | A, B, C, D | — | — |
| 3UO9 | Crystal structure of human gac in complex with glutamate and bptes | x-ray diffraction | A, B, C, D | — | — |
| 3VOY | Crystal structure of human glutaminase in apo form | x-ray diffraction | A | — | — |
| 3VOY | Crystal structure of human glutaminase in apo form | x-ray diffraction | A | — | — |
| 3VOZ | Crystal structure of human glutaminase in complex with BPTES | x-ray diffraction | A | — | — |
| 3VOZ | Crystal structure of human glutaminase in complex with bptes | x-ray diffraction | A | — | — |
| 3VP0 | Crystal structure of human glutaminase in complex with L-glutamine | x-ray diffraction | A | — | — |
| 3VP0 | Crystal structure of human glutaminase in complex with L-glutamine | x-ray diffraction | A | — | — |
| 3VP1 | Crystal structure of human glutaminase in complex with L-glutamate and BPTES | x-ray diffraction | A | — | — |
| 3VP1 | Crystal structure of human glutaminase in complex with L-glutamate and bptes | x-ray diffraction | A | — | — |
| 3VP2 | Crystal structure of human glutaminase in complex with inhibitor 2 | x-ray diffraction | A | — | — |
| 3VP2 | Crystal structure of human glutaminase in complex with inhibitor 2 | x-ray diffraction | A | — | — |
| 3VP3 | Crystal structure of human glutaminase in complex with inhibitor 3 | x-ray diffraction | A | — | — |
| 3VP3 | Crystal structure of human glutaminase in complex with inhibitor 3 | x-ray diffraction | A | — | — |
| 3VP4 | Crystal structure of human glutaminase in complex with inhibitor 4 | x-ray diffraction | A | — | — |
| 3VP4 | Crystal structure of human glutaminase in complex with inhibitor 4 | x-ray diffraction | A | — | — |
| 4O7D | Crystal structure of human glutaminase in complex DON | x-ray diffraction | A | — | — |
| 4O7D | Crystal structure of human glutaminase in complex don | x-ray diffraction | A | — | — |
| 5D3O | Crystal structure of full length human glutaminase C expressed in E.coli | x-ray diffraction | A, B | — | 8 (best 0.72) |
| 5D3O | Crystal structure of full length human glutaminase C expressed in E.COLI | x-ray diffraction | A, B | — | — |
| 5FI2 | Crystal structure of human GAC in complex with inhibitor UPGL_00009… | x-ray diffraction | A, B, C, D | 5XX | — |
| 5FI2 | Crystal structure of human gac in complex with inhibitor UPGL_00009… | x-ray diffraction | A, B, C, D | — | — |
| 5FI6 | Crystal structure of human GAC in complex with inhibitor UPGL_00011… | x-ray diffraction | A, B, C, D | 5XY | — |
| 5FI6 | Crystal structure of human gac in complex with inhibitor UPGL_00011… | x-ray diffraction | A, B, C, D | — | — |
| 5FI7 | Crystal structure of human GAC in complex with inhibitor UPGL_00015… | x-ray diffraction | A, B, C, D | 5XZ | 15 (best 0.73) |
| 5FI7 | Crystal structure of human gac in complex with inhibitor UPGL_00015… | x-ray diffraction | A, B, C, D | — | — |
| 5HL1 | Crystal structure of glutaminase C in complex with inhibitor cb-839 | x-ray diffraction | A, B, C, D | — | — |
| 5I94 | Crystal structure of human glutaminase C in complex with the inhibitor UPGL-00019 | x-ray diffraction | A, B, C, D | 69V | 12 (best 0.82) |
| 5I94 | Crystal structure of human glutaminase C in complex with the inhibitor upgl-00019 | x-ray diffraction | A, B, C, D | — | — |
| 5JYO | Allosteric inhibition of Kidney Isoform of Glutaminase | x-ray diffraction | D, A, B, C, E, F, G, H | 63J | 16 (best 0.80) |
| 5JYO | Allosteric inhibition of kidney isoform of glutaminase | x-ray diffraction | D, A, B, C, E, F, G, H | — | — |
| 5JYP | Allosteric inhibition of Kidney Isoform of Glutaminase | x-ray diffraction | A | ZBS | 1 (best 0.55) |
| 5JYP | Allosteric inhibition of kidney isoform of glutaminase | x-ray diffraction | A | — | — |
| 5U0I | C-terminal ankyrin repeats from human kidney-type glutaminase (KGA) - tetragonal crystal form | x-ray diffraction | A, B | CL, NA | — |
| 5U0I | C-terminal ankyrin repeats from human kidney-type glutaminase (kga) - tetragonal crystal form | x-ray diffraction | A, B | CL, NA | — |
| 5U0J | C-terminal ankyrin repeats from human kidney-type glutaminase (KGA) - monoclinic crystal form | x-ray diffraction | A, B, C, D | NA | — |
| 5U0J | C-terminal ankyrin repeats from human kidney-type glutaminase (kga) - monoclinic crystal form | x-ray diffraction | A, B, C, D | NA | — |
| 5UQE | Multidomain structure of human kidney-type glutaminase(KGA/GLS) | x-ray diffraction | A, B, C, D, F | 04A | 20 (best 0.80) |
| 5UQE | Multidomain structure of human kidney-type GLUTAMINASE(KGA/GLS) | x-ray diffraction | A, B, C, D, F | 04A | — |
| 5WJ6 | Crystal structure of glutaminase C in complex with inhibitor 2-phenyl… | x-ray diffraction | A, B, C, D | B4A | — |
| 6LOX | Crystal structure of human glutaminase with macrocyclic inhibitor | x-ray diffraction | A, B, C, D | EN3 | — |
| 6UJG | Crystal structure of human GAC in complex with inhibitor UPGL00012 | x-ray diffraction | A, B, C, D, E, F, G, H | Q9A | — |
| 6UJG | Crystal structure of human gac in complex with inhibitor UPGL00012 | x-ray diffraction | A, B, C, D, E, F, G, H | Q9A | — |
| 6UJM | Crystal structure of human gac in complex with inhibitor UPGL00013 | x-ray diffraction | A, B, C, D | Q94 | — |
| 6UK6 | Crystal structure of human GAC in complex with inhibitor UPGL00018 | x-ray diffraction | A, B, C, D | Q9S | 19 (best 0.81) |
| 6UK6 | Crystal structure of human gac in complex with inhibitor UPGL00018 | x-ray diffraction | A, B, C, D | Q9S | — |
| 6UKB | Crystal structure of human gac in complex with inhibitor UPGL00012 | x-ray diffraction | A, B, C, D | Q9V | — |
| 6UL9 | Crystal structure of human GAC in complex with inhibitor UPGL00023 | x-ray diffraction | A, B, C, D | Q9M | 14 (best 0.78) |
| 6UL9 | Crystal structure of human gac in complex with inhibitor UPGL00023 | x-ray diffraction | A, B, C, D | Q9M | — |
| 6ULA | Crystal structure of human gac in complex with inhibitor UPGL00012 | x-ray diffraction | A, B, C, D, E, G, F, H | QA4 | — |
| 6ULJ | Crystal structure of human GAC in complex with inhibitor UPGL00012 | x-ray diffraction | A, B, C, D | QAA | 13 (best 0.80) |
| 6ULJ | Crystal structure of human gac in complex with inhibitor UPGL00012 | x-ray diffraction | A, B, C, D | QAA | — |
| 6UMC | Crystal structure of human GAC in complex with inhibitor UPGL00012 | x-ray diffraction | A, B, C, D | U27 | 11 (best 0.80) |
| 6UMC | Crystal structure of human gac in complex with inhibitor UPGL00012 | x-ray diffraction | A, B, C, D | U27 | — |
| 6UMD | Crystal structure of human GAC in complex with inhibitor UPGL00012 | x-ray diffraction | A, B, C, D | QAJ | 15 (best 0.77) |
| 6UMD | Crystal structure of human gac in complex with inhibitor UPGL00012 | x-ray diffraction | A, B, C, D | QAJ | 15 (best 0.78) |
20 records more on the page itself.
Ligands
- 04A · N,N'-[sulfanediylbis(ethane-2,1-diyl-1,3,4-thiadiazole-5,2-diyl)]bis(2-phenylacetamide) · in 5 records
- NA · Sodium ion · in 4 records
- QAJ · 2-(pyridin-3-yl)-N-(5-{4-[(5-{[(pyridin-3-yl) acetyl]amino}-1,3,4-thiadiazol-2-yl)amino]piperidin-1-yl}-1,3,4-thiadiazol-2-yl)acetamide · in 4 records
- GLN · Glutamine · in 3 records
- SO4 · Sulfate ion · in 3 records
- 5XX · 2-phenyl-~{N}-[5-[[(3~{R})-1-[5-(2-phenylethanoylamino)-1,3,4-thiadiazol-2-yl]pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]ethanamide · in 2 records
- B4A · 2-phenyl-N-{5-[4-({5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl}amino)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide · in 2 records
- CL · Chloride ion · in 2 records
- PO4 · Phosphate ion · in 2 records
- Q9A · N-{5-[(3S)-3-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]amino}pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide · in 2 records
- Q9M · 2-phenyl-N-{5-[(1-{5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl}azetidin-3-yl)oxy]-1,3,4-thiadiazol-2-yl}acetamide · in 2 records
- Q9S · 5-{4-[(5-amino-1,3,4-thiadiazol-2-yl)oxy]piperidin-1-yl}-1,3,4-thiadiazol-2-amine · in 2 records
- QAA · 2-phenyl-N-{6-[4-({6-[(phenylacetyl)amino]pyridazin-3-yl}oxy)piperidin-1-yl]pyridazin-3-yl}acetamide · in 2 records
- QAM · N-(5-{[1-(5-amino-1,3,4-thiadiazol-2-yl)piperidin-4-yl]oxy}-1,3,4-thiadiazol-2-yl)-2-phenylacetamide · in 2 records
- U27 · 2-phenyl-N-{5-[(3R)-3-({5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl}oxy)pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide · in 2 records
- 5XY · 2-phenyl-~{N}-[5-[[(3~{S})-1-[5-(2-phenylethanoylamino)-1,3,4-thiadiazol-2-yl]pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]ethanamide · in 1 record
- 5XZ · 2-phenyl-~{N}-[5-[(3~{S})-3-[[5-(2-phenylethanoylamino)-1,3,4-thiadiazol-2-yl]oxy]pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl]ethanamide · in 1 record
- 63J · 2-(pyridin-2-yl)-N-(5-{4-[6-({[3-(trifluoromethoxy)phenyl]acetyl}amino)pyridazin-3-yl]butyl}-1,3,4-thiadiazol-2-yl)acetamide · in 1 record
- 69V · 2-phenyl-N-{5-[4-({5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl}oxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide · in 1 record
- EN3 · (E)-15,22-dioxa-4,11-diaza-5(2,5)-thiadiazola-10(3,6)-pyridazina-1,14(1,3)-dibenzenacyclodocosaphan-18-ene-3,12-dione · in 1 record
- HZO · 2,2-dimethyl-1,3-dihydrobenzo[a]phenanthridin-4-one · in 1 record
- Q94 · N-{5-[(3R)-3-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]amino}pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide · in 1 record
- Q9V · N-[5-(4-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]oxy}piperidin-1-yl)-1,3,4-thiadiazol-2-yl]acetamide · in 1 record
- QA4 · 2-cyclopropyl-N-{5-[4-({5-[(cyclopropylacetyl)amino]-1, 3,4-thiadiazol-2-yl}oxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide · in 1 record
- R0C · (2~{S})-2-methoxy-2-phenyl-~{N}-[5-[[(3~{R})-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]ethanamide · in 1 record
- R90 · ~{N}-[5-[[(3~{R})-1-(5-azanyl-1,3,4-thiadiazol-2-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]-2-phenyl-ethanamide · in 1 record
- V4I · 3-[2-oxidanylidene-2-[[5-[[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]amino]ethyl]benzoic acid · in 1 record
- ZBS · 2-phenyl-~{N}-[5-[(1~{S},3~{S})-3-[5-(2-phenylethanoylamino)-1,3,4-thiadiazol-2-yl]cyclohexyl]-1,3,4-thiadiazol-2-yl]ethanamide · in 1 record
Experiment against prediction
- 8BSL chain C against the predicted model O94925: TM-score 1.00, RMSD 0.40 Å
- 8JUB chain C against the predicted model O94925: TM-score 1.00, RMSD 0.41 Å
- 8BSM chain A against the predicted model O94925: TM-score 1.00, RMSD 0.38 Å
- 8BSL chain B against the predicted model O94925: TM-score 1.00, RMSD 0.43 Å
- 7SBM chain B against the predicted model O94925: TM-score 1.00, RMSD 0.43 Å
- 8BSK chain A against the predicted model O94925: TM-score 1.00, RMSD 0.39 Å
- 8JUB chain B against the predicted model O94925: TM-score 1.00, RMSD 0.46 Å
- 8BSL chain D against the predicted model O94925: TM-score 1.00, RMSD 0.47 Å
- 7SBM chain A against the predicted model O94925: TM-score 1.00, RMSD 0.48 Å
- 5D3O chain A against the predicted model O94925: TM-score 1.00, RMSD 0.46 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.